KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary

Stay informed about new Trial Results Summaries with our email notification service

Country	Location
Chile, Region M. de Santiago	Santiago, Region M. de Santiago, Chile, 7560908
China, Sichuan	Chengdu, Sichuan, China, 610066
Finland, Pohjois-Savo	Kuopio, Pohjois-Savo, Finland, 70200
Finland, Uusimaa	Helsinki, Uusimaa, Finland, 00290
Finland, Varsinais-Suomi	Turku, Varsinais-Suomi, Finland, 20520
Hong Kong, N/A	Kowloon, N/A, Hong Kong, N/A
Hong Kong, N/A	Pokfulam, N/A, Hong Kong, N/A
Korea, Republic of, Seoul	Seoul, Korea, Republic of, 03722
Netherlands, Overijssel	Deventer, Overijssel, Netherlands, 7416 SE
Netherlands, Zuid-Holland	Leiden, Zuid-Holland, Netherlands, 2333 ZA
Spain, Sevilla	Sevilla, Spain, 41009
Turkey, Adana	Adana, Turkey, 34010
Turkey, Ankara	Ankara, Turkey, 6230
Turkey, Ankara	Ankara, Turkey, 06680
Ukraine, Cherkaska oblast	Cherkasy, Cherkaska oblast, Ukraine, 18009
Ukraine, Dnipropetrovska oblast	Kryvyi Rih, Dnipropetrovska oblast, Ukraine, 50000
Ukraine, Ivano-Frankivska oblast	Ivano-Frankivsk, Ivano-Frankivska oblast, Ukraine, 76018
Ukraine, Kirovohradska oblast	Kropyvnytskyi, Kirovohradska oblast, Ukraine, 25011
Ukraine, Kyiv	Kyiv, Ukraine, 03022
Ukraine, Kyiv	Kyiv, Ukraine, 03151
Ukraine, Lvivska oblast	Lviv, Lvivska oblast, Ukraine, 79059
Ukraine, Vinnytska oblast	Vinnitsya, Vinnytska oblast, Ukraine, 21029
Ukraine, Zakarpatska oblast	Uzhhorod, Zakarpatska oblast, Ukraine, 88000
United States, FL	Clermont, FL, United States, 34711
United States, ND	Fargo, ND, United States, 58102
United States, SD	Sioux Falls, SD, United States, 57104